BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27498622)

  • 1. Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A.
    Metcalfe HJ; Steinbach S; Jones GJ; Connelley T; Morrison WI; Vordermeier M; Villarreal-Ramos B
    Vaccine; 2016 Aug; 34(38):4520-4525. PubMed ID: 27498622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ag85A-specific CD4
    Metcalfe HJ; Biffar L; Steinbach S; Guzman E; Connelley T; Morrison I; Vordermeier HM; Villarreal-Ramos B
    Vaccine; 2018 May; 36(20):2850-2854. PubMed ID: 29655632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
    Dean G; Whelan A; Clifford D; Salguero FJ; Xing Z; Gilbert S; McShane H; Hewinson RG; Vordermeier M; Villarreal-Ramos B
    Vaccine; 2014 Mar; 32(11):1304-10. PubMed ID: 24269321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
    Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
    Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model.
    Dou J; Tang Q; Yu F; Yang H; Zhao F; Xu W; Wang J; Hu W; Hu K; Liou C; Feng He X; Wang Y
    Immunobiology; 2010; 215(2):133-42. PubMed ID: 19450898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.
    Pérez de Val B; Villarreal-Ramos B; Nofrarías M; López-Soria S; Romera N; Singh M; Abad FX; Xing Z; Vordermeier HM; Domingo M
    Clin Vaccine Immunol; 2012 Sep; 19(9):1339-47. PubMed ID: 22761299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
    Gartner T; Baeten M; Otieno S; Revets H; De Baetselier P; Huygen K
    Immunol Lett; 2007 Jul; 111(1):26-35. PubMed ID: 17570535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
    Beveridge NE; Price DA; Casazza JP; Pathan AA; Sander CR; Asher TE; Ambrozak DR; Precopio ML; Scheinberg P; Alder NC; Roederer M; Koup RA; Douek DC; Hill AV; McShane H
    Eur J Immunol; 2007 Nov; 37(11):3089-100. PubMed ID: 17948267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
    Zhang M; Dong C; Xiong S
    Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.
    Tan K; Liang J; Teng X; Wang X; Zhang J; Yuan X; Fan X
    Hum Vaccin Immunother; 2014; 10(2):391-8. PubMed ID: 24192709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
    Santosuosso M; McCormick S; Zhang X; Zganiacz A; Xing Z
    Infect Immun; 2006 Aug; 74(8):4634-43. PubMed ID: 16861651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
    Vordermeier HM; Villarreal-Ramos B; Cockle PJ; McAulay M; Rhodes SG; Thacker T; Gilbert SC; McShane H; Hill AV; Xing Z; Hewinson RG
    Infect Immun; 2009 Aug; 77(8):3364-73. PubMed ID: 19487476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of the immune strategy based on BCG priming and Ag85A/GM-CSF DNA vaccine boosting in mice].
    Tang Q; Dou J; Zhao FS; Chu LL; Pan M; Wang YF
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jul; 23(7):591-4. PubMed ID: 17618574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
    Khanna M; Rady H; Dai G; Ramsay AJ
    Vaccine; 2021 Mar; 39(12):1780-1787. PubMed ID: 33632562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.